Shanghai Mabgen Biopharmaceutical Technology Co., Ltd.

This early-phase study tests a new drug called MG2512 in about 116 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see how the body processes it. This is a first step to see i…